

6 May 2016

GlucoControl™ Pre-Meal Drink Launched Now Available in Australian Pharmacies

Highlights

- GlucoControl™ product launch held in Melbourne
- The clinically proven product is now available in pharmacies across Australia
- More than 2.5m Australians living with type 2 diabetes or pre-diabetes

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Omniblend Innovation, the medical technology company focused on foods for special medical purposes, in which EVE holds a ~25% interest, increasing to a ~40% holding by 30 September 2016. Omniblend Innovation and Faulding recently held a joint product launch. Victorian MP for Broadmeadows and Parliamentary Secretary for Medical Research was in attendance to help launch Omniblend Innovation's flagship product GlucoControl™.



Picture 1: Frank McGuire, Member for Broadmeadows and Parliamentary Secretary for Medical Research launching GlucoControl™

GlucoControl™ Product Launch

Omniblend Innovation, is celebrating the launch of its flagship product, a clinically-validated, natural pre-meal drink designed to lessen the burden of managing type 2 diabetes (T2D). The drink is being distributed first in Australia by leading healthcare solution provider Faulding as GlucoControl™ and is available now at Chemmart pharmacy and other independent pharmacies.

Made with safe, food-grade ingredients, GlucoControl™ provides:

- A natural food product that makes it easier for those with type 2 diabetes to maintain their recommended diet
- A 35% reduction in post meal Glycemic Index in people with type 2 diabetes or pre-diabetes
- Longer feelings of fullness, with clinical studies showing no weight gain with regular use

“When we first heard about this product we recognised its potential right away,” said **Andrew Vidler**, General Manager Endeavour Consumer Health.

“We’re thrilled to have partnered with Omniblend Innovation and its food technology innovators to make Faulding GlucoControl more accessible for Australian consumers and believe it will have a positive impact on people wanting to reduce meal GI levels.”



Picture 2: GlucoControl™ is now available in pharmacies across Australia

GlucoControl™ Development

Type 2 diabetes is one of Australia’s most prevalent and fast growing chronic diseases, with more than 200 Australians developing the condition every day. Over 1 million Australians currently have type 2 diabetes and an additional 1.5 million have pre-diabetes.

GlucoControl™ is a pre-meal drink designed for the dietary management of people who are pre-diabetic or with moderately well controlled Type-2 diabetes and is to be taken under the medical supervision of a person’s health care professional as part of a recommended diabetes diet.

A result of six years of development and more than \$5 million in research and development, GlucoControl™ forms a persistent protein-rich layer on the walls of the gastrointestinal tract that regulates the blood glucose spike after a meal for people with type 2 diabetes and pre-diabetes. It is designed for the dietary management of people with pre-diabetes or with moderately well-controlled Type-2 diabetes.

The first-to-market product was developed by Victorian-based company Omniblend Innovation and its team of medical researchers and food scientists, and has been tested and validated under the guidance of Professor Peter Clifton of the Baker IDI Heart and Diabetes Institute.

Faulding GlucoControl™ is manufactured in Australia by Omniblend, which won a major Government grant to help commercialise the product in 2012.

Unlike other pre-meal drinks, it contains only 16g of protein, measures around 155ml when mixed, and can be taken immediately before, or up to 30 minutes before, a meal.

“Faulding and Omniblend Innovation are both committed to providing Australians with diverse healthcare solutions,” said **Arie Nudel**, Managing Director of Omniblend Innovation.

“We are delighted to have Faulding supporting us in this venture. Together we are working to ensure this product has a positive impact on as many lives as possible, both here and overseas.”

Mr Vidler said the product was an important step forward for the iconic Faulding brand.

“It reflects our ongoing commitment to helping Australians manage their health and also helping the Australian industry when sourcing new and innovative products,” Mr Vidler said.

Clinically Validated

A study to determine the efficacy of GlucoControl™ was undertaken by researchers at Baker IDI Heart and Diabetes Institute in Melbourne, an international pioneer in diabetes epidemiology and treatment.

Experts involved in clinical trials of GlucoControl™ say the product’s unique properties enable a number of key benefits:

“What we are seeing...in these [trial] patients is a substantial lowering of their postprandial glucose response.” - **Professor Chris Rayner**, Gastroenterologist, University of Adelaide

“...this formulation does slow gastric emptying and that slowing of gastric emptying leads to a reduction in postprandial glucose, which is substantial. Their Glycated hemoglobin was improved using this treatment.” - **Professor Michael Horowitz**, Professor of Medicine and Head Endocrine Unit, University of Adelaide

“What’s indisputable is that if you flatten the glycemic curve, your HBA1C should be lower...” - **Professor Peter Clifton**, School of Pharmacy and Medical Sciences, University of South Australia

GlucoControl™ is available in Australian pharmacies now.

Product Launch Video

Please visit the EVE Investments Youtube page by copying the below address into your browser to view a product video which was shown at the GlucoControl™ launch.

Address: [youtube.com/watch?v=v6QPzDQvwbQ](https://www.youtube.com/watch?v=v6QPzDQvwbQ)

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments